Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03940703 · ClinicalTrials.gov registry record · Phase 2
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by EMD Serono Research & Development Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
- 20
- Study locations
NCT03940703 is a Phase 2 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by EMD Serono Research & Development Institute. The registered enrollment target is 140 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT03940703, a Phase 2 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by EMD Serono Research & Development Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study was to assess the antitumor activity, safety, tolerability, and pharmacokinetics (PK) of the Mesenchymal-epithelial Transition Factor (MET) inhibitor tepotinib combined with the 3rd generation EGFR inhibitor osimertinib in participants with advanced or metastatic non-small cell lung cancer (NSCLC).
Conditions Studied
Interventions
- DRUG Osimertinib
- DRUG Tepotinib
Study Locations (20)
California
- Compassionate Care Research Group Inc - Edinger Medical Group, Inc. - Fountain Valley
- Memorial Care - Long Beach
- Ventura County Hematology Oncology Specialists - Oxnard
- Innovative Clinical Research Institute - Whittier
Florida
- Holy Cross - Fort Lauderdale
- Memorial Healthcare System - Hollywood
- Cancer Specialists of North Florida - Jacksonville
- Ocala Oncology - Ocala
Indiana
- Fort Wayne Medical Oncology and Hematology - Fort Wayne
- Community Health Network - Indianapolis
- Beacon Health - South Bend
Maryland
- Medstar Franklin Square Clinical Research Center - Baltimore
- The Center for Cancer & Blood Disorders - Maryland - Bethesda
Arizona
- Yuma Regional Medical Center - Yuma
Connecticut
- Eastern Connecticut Hematology & Oncology Associates - Norwich
Georgia
- University Cancer and Blood Center - Athens
Hawaii
- Hawaii Cancer Care - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2019-09-19 |
| Est. Completion | 2026-05-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03940703
The ClinicalTrials.gov registry entry for NCT03940703 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (79% lower). The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Osimertinib is the first listed.
NCT03940703 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Indiana.
Frequently Asked Questions
What is clinical trial NCT03940703 about?
NCT03940703 is a clinical study titled "A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)". This study was to assess the antitumor activity, safety, tolerability, and pharmacokinetics (PK) of the Mesenchymal-epithelial Transition Factor (MET) inhibitor tepotinib combined with the 3rd generation EGFR inhibitor osimertinib in participants with advanced or metastatic non-small cell lung cance...
What is the current status of trial NCT03940703?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2019-09-19. Estimated completion is 2026-05-01.
What conditions does trial NCT03940703 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT03940703?
The interventions under investigation include: Osimertinib (DRUG), Tepotinib (DRUG).
Who is sponsoring clinical trial NCT03940703?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03940703 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.